Your Genes Dictate Drug Effectiveness

The enzyme CYP2C19, found in the liver, plays a crucial role in activating swallowed medications. However, its efficiency varies significantly among individuals, determined by their unique genetic makeup. This variability has historically led to inconsistent drug efficacy, with doctors often unaware of the underlying reasons.

Advancements in genome sequencing and pharmacogenomics, the study of how genes influence drug interactions, have dramatically changed this landscape. These fields allow for the identification of specific gene variations that impact how a person metabolizes medications. For instance, roughly half of South Asians are intermediate or poor metabolizers of CYP2C19, potentially reducing the effectiveness of critical drugs like clopidogrel and increasing heart attack risk.

Similarly, certain genetic variants affect folate metabolism in about one-third of Indians, hindering the activation of folic acid. Other gene variants, like those in SLCO1B1, can cause severe muscle pain in response to statins, leading to a misdiagnosis of non-compliance. These examples highlight how standard prescriptions represent an average, not an individual's specific needs.

Tests like Mira One and its competitors in India offer doctors more precise information, enabling a shift from average-based prescribing to personalized medicine. Sequencing one's genome provides a lifelong health asset. While not predictive of future health events, these tests offer a sharper starting point for medical decisions. The cost, such as ₹1 lakh for Mira One, should be weighed against the potential for improved treatment decisions over decades.